He was in fact a professor of dermatology prior to entering the biotech field.
One has to ask the question, what was the nature of his association and recent investment ( very sizable as you all know) with Dr. Cauwenbergh and RXI ?
At the time of the asset deal just a few months ago, RXI-109 was just completing its Ph1 trial. Would Frost have proceeded with RXI if he were not confident in the future of rxi-109?
Just my thought this morning. good luck All.
Another Frost Pick OMER was up 68% today ( .... that's 68%in one day). OMER is an eye surgery drug.